2-[4-[4-[4-[2-(4-methoxyphenyl)phenyl]piperazin-1-yl]butoxy]phenyl]imidazo[1,2-a]pyridine
C34H36N4O2 — CID 162666163
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-[4-[4-[4-[2-(4-methoxyphenyl)phenyl]piperazin-1-yl]butoxy]phenyl]imidazo[1,2-a]pyridine
2-[4-[4-[4-[2-(4-methoxyphenyl)phenyl]piperazin-1-yl]butoxy]phenyl]imidazo[1,2-a]pyridine (PubChem CID 162666163) has the molecular formula C34H36N4O2 and a molecular weight of 532.69 g/mol. Its IUPAC name is 2-[4-[4-[4-[2-(4-methoxyphenyl)phenyl]piperazin-1-yl]butoxy]phenyl]imidazo[1,2-a]pyridine.
Molecular Properties
| Compound Name | 2-[4-[4-[4-[2-(4-methoxyphenyl)phenyl]piperazin-1-yl]butoxy]phenyl]imidazo[1,2-a]pyridine |
|---|---|
| PubChem CID | 162666163 |
| Molecular Formula | C34H36N4O2 |
| Molecular Weight | 532.69 g/mol |
| Exact Mass | 532.28 |
| IUPAC Name | 2-[4-[4-[4-[2-(4-methoxyphenyl)phenyl]piperazin-1-yl]butoxy]phenyl]imidazo[1,2-a]pyridine |
| SMILES | COc1ccc(-c2ccccc2N2CCN(CCCCOc3ccc(-c4cn5ccccc5n4)cc3)CC2)cc1 |
| InChI | InChI=1S/C34H36N4O2/c1-39-29-15-11-27(12-16-29)31-8-2-3-9-33(31)37-23-21-36(22-24-37)19-6-7-25-40-30-17-13-28(14-18-30)32-26-38-20-5-4-10-34(38)35-32/h2-5,8-18,20,26H,6-7,19,21-25H2,1H3 |
| InChIKey | VQZAUMPXCBBUBJ-UHFFFAOYSA-N |
| XLogP | 6.66 |
| TPSA | 42.24 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 10 |
| Heavy Atoms | 40 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 532.69 |
| LogP ≤ 5 | 6.66 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 6 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'Aliphatic_long_chain', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 162666163 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.